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Background: Proton Pump Inhibitor use is increasing in the hospital setting. This has coincided with an
increase in Clostridium difficile-associated diarrhea (CDAD). C. difficile is a growing problem in hospitals,
despite health care workers taking extra steps to wash hands and use personal, protective equipment in patient
rooms. Known risk factors for the development of C. difficile infection are being carefully reviewed and
considered. Upset of the normal intestinal flora is a known risk factor for the development of CDAD. In
addition, a controversial risk factor has been proposed: Proton Pump Inhibitors (PPI).
Hypothesis: Hypochlorhydria from PPI is a risk factor for developing CDAD.
Study Design: Systematic review of available medical literature and reviews.
Methods: An extensive literature search was conducted on Medline-OVID, CINAHL (EBSCOhost), and
PubMed using the search terms “proton pump inhibitor and Clostridium difficile”, “Proton Pump Inhibitors”,
and “Clostridium difficile”. Relevant references were retrieved and references from the reviewed clinical trials
listed were used as sources for this paper.
Results: The majority of the clinical trials in the literature today show a strong association with PPI-induced
hypochlorhydria inducing CDAD. Of the nine papers discussed in this review, seven showed strong
associations with significance, while only two trials showed no association with PPI use and CDAD.
Conclusion: There is a strong correlation between PPI-induced hypochlorhydria and CDAD. With this
confirmation of such a strong association, a randomized controlled trial should be done to confirm these
results.
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Abstract   
Background:  Proton Pump Inhibitor use is increasing in the hospital setting. This has 
coincided with an increase in Clostridium difficile-associated diarrhea (CDAD). C. 
difficile is a growing problem in hospitals, despite health care workers taking extra steps 
to wash hands and use personal, protective equipment in patient rooms. Known risk 
factors for the development of C. difficile infection are being carefully reviewed and 
considered. Upset of the normal intestinal flora is a known risk factor for the 
development of CDAD.  In addition, a controversial risk factor has been proposed: 
Proton Pump Inhibitors (PPI). Hypothesis:  Hypochlorhydria from PPI is a risk factor for 
developing CDAD.  Study Design:  Systematic review of available medical literature 
and reviews. Methods:  An extensive literature search was conducted on Medline-OVID, 
CINAHL (EBSCOhost), and PubMed using the search terms “proton pump inhibitor and 
Clostridium difficile”, “Proton Pump Inhibitors”, and “Clostridium difficile”.  Relevant 
references were retrieved and references from the reviewed clinical trials listed were used 
as sources for this paper. 
Results: The majority of the clinical trials in the literature today show a strong 
association with PPI-induced hypochlorhydria inducing CDAD. Of the nine papers 
discussed in this review, seven showed strong associations with significance, while only 
two trials showed no association with PPI use and CDAD. Conclusion:  There is a strong 
correlation between PPI-induced hypochlorhydria and CDAD. With this confirmation of 
such a strong association, a randomized controlled trial should be done to confirm these 
results.  Keywords:  Proton Pump Inhibitors, Clostridium difficile, hypochlorhydria 
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Proton Pump Inhibitor Association with Increased Risk of Clostridium difficile 
Associated Diarrhea 
 
Introduction 
 
The use of Proton Pump Inhibitors (PPIs) and outcomes of C. difficile associated diarrhea (CDAD) 
have come under close investigation over the past 10 years.  Recent literature is showing the likelihood 
for the PPIs inducing hypochlorhydria which, in turn, might be inducing CDAD.  A good practitioner 
of medicine should have a sound evidence base from which to practice. The questions must be 
postulated: What is the association between PPI use and CDAD? Is there good evidence to show an 
association? Does a clinical trial need to be run to provide an answer?  
Overview and history of Proton Pump Inhibitors 
Wolfe’s article1 shows that Proton Pump Inhibitors have been used for the treatment of acid-related 
disorders both in outpatient and inpatient settings since their introduction in the late 1980s. Currently, 
PPIs are indicated by the FDA for use in the following acid-related disorders: Peptic ulcer disease, 
eradication of Heliobacter pylori, treatment and prevention of gastroduodenal ulcers associated with 
NSAID use, Zollinger-Ellison syndrome, and finally the treatment of gastroesophageal reflux disease.1 
  Use of PPIs has become increasingly common over the past 10 years in the hospital setting.  Recently 
PPIs have been proven to have a well defined role in the prevention of stress ulcers in critical care 
patients. 2 
 Metz demonstrated that PPIs have potential adverse effects that fall into four main categories. 
The first is idiosyncratic reactions to PPI-induced interstitial nephritis, hepatitis, or allergy which are 
unpredictable and very uncommon. The second is drug-to-drug interactions, and is very predictable. 
Drug-induced reflex hyper-gastrinemia is expected when gastric acid secretion is inhibited and is the 
third potential adverse effect.  The fourth, and the focus of this paper, is a drug-induced 
hypochlorhydria.3 
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 Hypochlorhydria is a low chloride amount in the gastric secretions, which causes an increase 
in gastrointestinal pH to more alkaline levels.  
Overview and history of Clostridium Difficile-Associated Diarrhea 
According to UpToDate, Clostridium difficile is an anaerobic gram-positive, spore-forming, toxin- 
producing bacillus that was first described in 1935. C. difficile exists in spore and vegetative forms. It 
survives in spore form outside the colon.  The bacillus spores are resistant to heat, acid, and antibiotics. 
Once spores are in the colon, they convert to their fully functional vegetative, toxin-producing forms 
and become susceptible to destruction by antimicrobial agents.1 CDAD has been an increasing problem 
in hospitalized patients.  McFarland, Mulligan, Kwok, and Stamm showed that nosocomial, or hospital 
acquired, C. difficile infections are frequently transmitted among hospitalized patients and that the 
organism is often present on the hands of hospital personnel caring for such patients. 4 With this, there 
is strong support for an increase in hand washing and personal protection to stop this increasing 
incidence in C. difficile infection. 
There are few risks that are recognized to be causes of C. difficile infection.  A trial by 
Poutanen and Simor noted that the most common risk factor associated with C. difficile infection is 
exposure to antibiotics, “especially those with broad-spectrum activity such as penicillins, 
cephalosporin’s and clindamycin.”  They also add that advanced age and severe underlying disease are 
independent risk factors for changes in fecal flora.5 
 The normal flora of the colon presents a strong defense and resistance to C. difficile infection.  
When the body becomes immunocompromised or there is a change in the normal flora, resistance to 
the bacterium is lost.  Any factor that alters the flora, such as a PPI inducing hypochlorhydria, will 
increase the risk of CDAD and infection.   
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Importance of exploring a link between PPI induced C. difficile 
PPIs are a relatively safe way to control dyspepsia, ulcers, and esophageal reflux.  PPIs have recently 
been added to gastrointestinal protocols within many hospitals around the United States, the United 
Kingdom, and Canada. With this increased use of PPIs, there has also been an increase in CDAD. 6 
PPIs may not change the outcome for patients in the short term, and many argue that they are safe, but 
with the “coincidental” increase in CDAD with PPI use, the question must be asked if these “harmless” 
drugs are actually causing harm. 
It is well documented that PPIs induce hypochlorhydria thus changing the pH of the colon.3,7 In 
fact, in 1982, before the introduction of PPIs, Aslam and Musher demonstrated that hypochlorhydric 
patients are at greater risk for transmission of CDAD.8 With the increased use of PPIs, this change in 
the colon environment is important because risks associated with longer stays in hospital, increased C. 
difficile resistance, and mortality resulting from C. difficile infection are all also on the rise. Aslam et 
al. also demonstrated that C. difficile produces one or more toxins that cause colonic inflammation, 
leading, in extreme cases, to necrosis with perforation.  C.difficile is an important cause of nosocomial 
morbidity and mortality and has been implicated in recent epidemics.  
Nardino, Vender, and Herbert conducted a trial in 2000, highlighting inappropriate use of 
GARD therapy in hospitalized patients. The trial determined that in 65% cases, PPIs prescribed, were 
not indicated. They concluded that a there is a significant overuse of GARD therapy in hospitalized 
patients.9 Grube and May did a clinical review in 2007 on stress ulcer prophylaxis in hospitalized 
patients. Their conclusion was that GARD therapy was misused in the hospital setting and that as 
many as 71% of all patients on general medicine wards were receiving some sort of GARD therapy 
without any indication. 10 
 The current changes in our healthcare system make it even more important to keep our hospital 
expenses low and the cost of treatment of disease must be taken into account. Heidelbaugh and 
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Inadomi stated that the cost of inappropriate stress ulcer prophylaxis in hospitalized medicine patients 
is approximately $44,096 annually.11  In 2008, Vonberg, Reichardt, Behnke, Schwab, Zindler, and 
Gastmeier looked at the total cost, per patient, of a CDAD positive patient in the hospital setting. They 
found that it is significantly different in length of hospital stays and in cost per patient. The average 
patient with CDAD will cost Euro 33, 840 (47,257 USD), while a patient without CDAD in the 
hospital will cost roughly Euro 7,147 (9,980 USD). 12  With these statistics, it is of the utmost 
importance to try to decrease the factors that increase the risk of CDAD. 
Methods 
 
An extensive literature search was conducted on Medline-OVID, CINAHL (EBSCOhost), and 
PubMed using the search terms “Proton Pump Inhibitor and Clostridium Difficile”, “Proton Pump 
Inhibitors”, “Clostridium Difficile”.  Relevant references were retrieved and references from clinical 
trials found were used as sources for this paper. 
The clinical trials were reviewed and assigned validity numbers according to Tables 2 and 3. 
Inclusion criteria include studies published in English, adults over age 18, studies conducted after 
1993, and currently hospitalized patients.  Most of the clinical trials systematically reviewed are from 
2007 and 2008, with one initial trial of importance in 1993. Clinical trials with patients both in the ICU 
and on a general medicine floor were included as well as trials that evaluated prophylactic use of PPIs, 
and trials that evaluated adverse events to include C. difficile.   Exclusion criteria include outpatient 
populations, child based trials, any trials before 1993, and non-English speaking trials. No upper age 
limit was set.  
Results 
 
A total of 10 trials (Table 1), including case studies, cohorts, and retrospective/prospective reviews 
were evaluated in this systematic review. The majority were conducted between 2002 and 2008.  The 
results from one trial, conducted in 1993, were reviewed, as it was one of the first studies to link PPIs 
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with C. difficile.  Most of the trials found associations between PPI use and subsequent C. difficile 
infection.  The literature addressed hospital inpatients that were exposed to a PPI to see if C. difficile 
was an outcome.  Patients with diagnosed C. difficile were retrospectively reviewed for PPI use.  Two 
reviews which comment on these associations were included. 
Strong links of PPIs and C. difficile 
Dial, Alrasadi, Manoukian, Huang, and Menzies ran a cohort trial where the cohort patients were 
identified from a pharmacy database that included all patients who received antibiotics while 
hospitalized on two general medical and one surgical ward at Royal Victoria Hospital in Montreal. 
Cohort patients were taken if their names appeared in the hospital infection control service registry 
with a positive toxin assay result for C. difficile.  Of the 1187 patients, eighty one (6.8%) developed 
CDAD.  Five hundred and ninety one patients were on PPIs.  Fifty five (9.3%) of the patients on PPI 
developed CDAD.  Five hundred and ninety six patients were not exposed to PPI and only twenty six 
of them (4.4%) developed CDAD.13 The relative risk of CDAD was higher among the patients who 
were prescribed PPIs than among those who were not prescribed those drugs.  A multivariate analysis 
was run to look at the antibiotics with known higher risk of CDAD development, the number of 
antibiotics given, and the ward.  CDAD remained significantly associated with the use of PPI (OR 2.1, 
95% CI 1.2-3.5).13 
Dial et al. also ran a retrospective case control study “to assess the possibility that proton pump 
inhibitors were prescribed to patients who were sicker and had other risk factors for C. difficile 
infection.” 13 The cases involved included all patients on all wards in the hospital who developed 
diarrhea with a positive C. difficile toxin assay result as diagnosed from a stool sample. The control 
group was selected from a list obtained from the hospital pharmacy of patients who had been 
prescribed any antibiotics while in hospital during the study period.  Ninety four cases were found with 
ninety four controls to match.  In the case group, sixty or (64%) were receiving PPIs while only thirty 
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four (36%) from the control group received PPIs. CDAD developed in one patient from the control 
group not receiving an antibiotic but who did receive a PPI.  Use of PPIs was associated with C. 
difficile with an adjusted OR 2.7, 95% CI 1.4-5.2, among other risk factors.13 
Jayatilaka, Eddi, Bakaj, Baddsura, and Debari did a 5 year analysis of C. difficile infection in 
inpatient adult populations. They ran an incidence and correlation study regarding gastric acid-
reducing agents, or GARD, and C. difficile infection. Relevant discharge summaries were reviewed 
based on a list of ICD-9 codes for patients positive with C. difficile. They observed that the usage of 
PPI increased substantially over the study period and correlated strongly with CDAD incidence, with a 
P=0.017, which is statistically significant.14  Any P value less than or equal to 0.05 is said to be 
statistically significant in all trials. 
Jayatilaka et al. also did a simultaneous one year case control study at the same institution 
during the final year of the five year analysis. Cases selected tested positive test for C. difficile toxin A 
or B and had associated episodes of diarrhea.  Two controls were selected for one case, where they 
were matched for admitting dates, age, and gender.  These two groups were further stratified by GARD 
use into H2 blockers and PPIs. Those two groups were further stratified according to those using 
GARD before or after admission. Of the 244 controls, 112(46%) were on PPI’s before admission, 
while eighty four (69%) of the 122 cases were on PPI’s. The association between PPI use and CDAD 
was analyzed using odds ratios. Univariate analysis was performed for patients on PPIs prior to 
hospital admission and the OR was 2.61 with a 95% CI of 1.65-4.12, while those on PPIs post-
admission had an OR of 2. 57 with a 95% CI of 1.45-4.12. 
Aseeri, Schroeder, Kramer, and Zackula looked at whether PPIs are a risk factor for CDAD. 
They ran a case controlled study of hospitalized patients who developed CDAD. Cases were identified 
as C. difficile toxin positive by Premier Toxin A and B enzyme immunoassay, with new onset of two 
or more loose bowel movements per day after admission for 3 days. The control group had the same 
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inclusion criteria, expect no diarrhea, with or without positive toxin. The control group was pair 
matched by admission date, antibiotic exposure, gender, age groups, ward, and room number at 
admission.  One hundred eighty-eight subjects were identified with ninety four cases and matched 
control. McNemar’s test for the association between gastric acid suppression therapy and CDAD 
showed a significant association with a P=0.030. The cases had 72 (76.6%) with PPI exposure, while 
the controls only had 40 patients or 42.6%. Risk factors were sparse in the results, so a multivariate 
exact conditional logistic regression was conducted.  The results showed that patients exposed to PPIs 
were 3.6 times more likely to develop CDAD. This result was expressed as OR3.6, 95% CI 1.7-8.3.15 
Choudhry, Soran, and Ziglam ran a prospective case series to evaluate the appropriateness of 
prescribing PPI to patients diagnosed with C. difficile. One hundred thirty eight hospitalized patients 
who developed CDAD were studied over a four month period. Eighty eight (64%) of the 138 patients 
who developed CDAD were on PPIs. The mean age was seventy six (ranged 35-97) and forty nine 
were female (55.7%). 90% of the patients were on a PPI for longer than four weeks. An appropriate 
indication for use of the PPI was only apparent in forty seven (53.4%) of these patients.6 
 Cadle, Mansouri, Logan, Kudva, and Musher ran a retrospective case series to evaluate the 
role of concurrent use of PPIs in the outcomes of treatment for CDAD.  This trial was conducted at a 
Veterans Affairs medical center in which C. difficile was diagnosed. One hundred and thirty eight of 
the 140 patients were male. The outcomes were evaluated as cured, did not respond to therapy, and 
disease recurrence to CDAD.  Ninety-seven (69%) of patients received a PPI and forty three (31%) did 
not. Of the patients receiving PPIs, thirty seven (38%) were cured, twenty (21%) did not respond, and 
40 (41%) had disease recurrence. Patients were 4.17 times as likely to have a recurrence of CDAD 
while taking a PPI.16 
Nachnani, Bulchandani, and Allen ran a retrospective case series to evaluate whether worse 
outcomes would result for patients taking PPIs who currently had CDAD or who developed it while in 
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the hospital.  Fifty-five consecutive patients had records reviewed who were diagnosed with CDAD.  
PPI use was considered if the patient had been on it for seven or more days before C. difficile was 
diagnosed. 26 (53%) of patients were on PPIs at admission. In this study, the use of PPIs were an 
independent and the  ONLY risk factor associated with longer hospital stays by almost 4.5 days, with a 
P=0.033.17 
No conclusive evidence of PPIs causing CDAD 
Beaulieu, Williamson, Pichette, and Lachaine ran a case series trial to determine whether use of gastric 
acid-suppressive agents increased the risk of CDAD. The subjects were C. difficile positive if they had 
diarrhea for more than twenty four hours and positive Premier Cytoclone A or B between two days 
after admission and up to two months after discharge. All patients were selected from the medical ICU.  
Eight hundred and twenty seven records were included in this trial.  The mean incidence of CDAD was 
8.4 per 1000 days in the hospital.  During the study, 335 patients received a PPI (40.5%), 470 (56.8%) 
received an H2-receptor antagonist, while 182 (22%) did not receive either medication. Hazard Ratios 
(HR) were done to evaluate the risks with PPIs.  The adjusted Hazard Ratio (aHR) was .89, 95% CI 
0.59-1.36. The result indicates that the likelihood of developing CDAD was not significantly different 
for patients taking PPIs or not taking PPIs. 18  
Simor, Yake, and Tsimidis ran an epidemiological study at a long-term and chronic care facility 
during 1981 and 1990. Five hundred and four individuals were submitted for C. difficile culture and 
cytotoxin assays, with 236 specimens from ninety four residents testing positive.  The number of 
patients taking anti-ulcer medications was 20 (of 94), while the number of residents taking anti-ulcer 
medications and not developing CDAD was 116.  The OR was 2.1 with a 95% CI of 0.7-2.1. The P=.5, 
which is not statistically significant, resulting in evidence for the proposition that anti-ulcer 
medications do not increase the risk for CDAD.19 However, the anti-ulcer medication probably was not 
a PPI, a significant piece of to trial.  
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Discussion 
 
The goal of this systematic review is to evaluate recent primary research to determine if the evidence 
suggests PPI induced hypochlorhydria is a risk factor for developing CDAD.  There is a shortage of 
cohort and case controlled trials in this area of medicine. There are commentaries and reviews in the 
literature that suggest an association between PPIs and CDAD, but were not included in this systematic 
review.     
 Dial, Aseeri, Jayatilaka, Choudhry, Cadle, and Nachanani had all run trials with showing 
associations of PPIs and a resultant CDAD.  Although a correlation was shown, this does not mean a 
direct causation. These finding show evidence for further trials to define a direct causal relationship of 
the PPI causing CDAD.  The study done to show deny any association of PPI inducing CDAD by 
Beulieu holds more weight than the epidemiology study done by Simor.  Both trials contradict the 
association of PPI inducing CDAD and they both identify the need for further study. 
The variability among the trials also makes it very difficult to evaluate this clinical question. 
Validity was difficult to determine on this variation of trials. The necessary questions were asked and 
evaluated in Table 2 for the cohorts and in Table 3 for the case controls. The cohorts were given a 
score for each of the questions answered with four of four being optimum score, two and three out of 
four were acceptable scores, and one or zero as unacceptable scores. Both cohort trials fell in the 
acceptable range.  The case control trials were validated on a scale out of three. Each question had one 
numerical value, as with the cohort. Three out of three was the best, two out of three was acceptable 
and one or zero was unacceptable. Both case control studies were in the acceptable.  
In the case series studies, a problem arose in determining validity.  It is impossible to determine 
whether the observed outcome would likely have occurred in the absence of exposure during case 
series studies.20 
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  Thus, the importance of recognizing that the results will generate questions for regulatory 
agencies and clinicians should not be dismissed.  Clinical investigators should make policy based on 
studies that are determined to be valid. The usefulness of these types of studies, case series, and 
reviews lies in pointing to future experiments that can be carried out under better conditions. 
Most of the trials evaluated showed a link with PPIs as risk factors for CDAD. The literature 
clearly demonstrates that the response to the critical question in this systematic review is in the 
affirmative.  Dial’s cohort carries the most weight.  After all the results were presented, they followed 
up with a multivariate analysis of antibiotics that are known to cause CDAD, such as cefazolin, 
florquinolones, Vancomycin, and second and third generation cephalosporin’s. After this multivariate 
analysis, it was still their conclusion that PPI use was strongly associated with the development of 
CDAD.  Controlling for the known risk factors gives the answers more influence.  The editorial on the 
trial done by Aseeri, written by David Metz, concludes with him proposing that the most important 
way to reduce risk of CDAD is for careful barrier nursing, hand washing among patients, and limiting 
unnecessary antibiotic exposure.3 
  He makes many good points throughout his paper and at the end of his editorial, in his conflict 
of interest statement, he states he has received grant support and honoraria from, among others, Astra 
Zeneca and Wyeth, who sell PPIs.  The literature is strong to support the association of PPI inducing 
hypochlorhydria in turn being a risk factor for CDAD.  With the evidence to show the poor outcomes 
on patients, longer hospital stays, and an increased financial burden on patients and on hospitals, this is 
a risk factor that should be eliminated. Further research must be done for more conclusive evidence, as 
described in the section for recommended further study.  
 
Limitations of Study 
 
The methodological limitations should be minimal, as both trials sponsored by hospitals and 
pharmaceutical companies were used, although some bias may remain.  This is not an RCT to give an 
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example of a population but a mere sampling of trials in the literature at this point in time. Systematic 
reviews of this issue alone cannot fully conclude whether or not PPIs should be used in hospital 
setting.  High quality RCTs must be done. 
Recommendations for further study 
 
Currently, the best types of trials used to explore this topic are cohort and case controls. These are 
good because studies including extremely large populations have been included.  The current gold 
standard for clinical trials is randomized controlled trials (RCT) which are the best way to evaluate a 
question with primary research. RCT are ideal because they have the least amount of bias, most control 
within the trial, and balanced measurements.    
Many hospitals have PPIs as part of the GI prophylaxis. If PPIs are out on so many protocols, 
an RCT should be done to evaluate this use of PPIs. The randomizations should be double-blinded in 
two groups with PPI use vs. placebo. The PPI should be the same one used for all patients.  The patient 
population should be those admitted to a medical or surgical ward, over the age of 18, and not 
currently taking a PPI. Patients should be recruited over a span of 2 years, to get accurate patient 
numbers.  Randomization should take place with a blinded randomization, such as an interactive voice 
response system (IVRS), through a telephone system.  The patients should be followed for as long as 
they are admitted to the hospital and through discharge after 2 months.  Patients should be followed to 
monitor any adverse events from the use of prophylactic PPI.  Many other known risk factors, for 
example, advanced age and antibiotic use, will need to be accounted for in the trial. The results should 
be monitored and controlled with univariate and multivariate analysis with controls for the known risk 
factors. Certain antibiotics should be taken into account, especially those known as risk factors for 
inducing CDAD. All patients should be followed up for evaluation and status. 
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Conclusion 
At this point, the evidence strongly suggests that hypochlorhydria induced by PPIs is a risk factor for 
CDAD.  With the evidence that PPIs are being used inappropriately and even with no indication at all, 
the risks outweigh the benefits. Something more needs to be done to further evaluate the risks. CDAD 
is a very important disease associated with nosocomial infections. While hand washing and personal 
protection are helpful ways to control the spread of disease, health care providers have a responsibility 
to eliminate any other risk factors for this devastating disease in our hospitals today. 
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Table 1-Comparison of Trials 
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Table 2 Cohort Validity 
 
 
COHORT DIAL Beaulieu 
Were patients similar for 
prognostic factors that are 
known to be associated 
with the outcome (stat 
adjustments made)? 
Yes,  patients taking PPIs and not 
taking PPIs were just as likely to be 
taking two or more, or antibiotics that 
have a high risk of causing C.diff 
diarrhea.  
Yes, they were all medical 
ICU patients. Although 
this, there were not 2 
specific groups to 
compare. It was Cdiff and 
lists of risk factors 
involved. 
Were the circumstances 
and methods for detecting 
the outcome similar 
Yes and surveillance bias was ruled 
out. C.Diff infection was identified by 
verifying names in the hospital's 
infection control registry. Addition to 
this list was a stool sample identified 
with a positive toxin assay. 
Yes, The study pop was 
composed of pt's in the 
MICU for >24hrs.  
Was the follow-up 
sufficiently complete 
Yes, Medication data was taken 30 
days before c. diff diagnosis.                                      
Outcomes were followed for 30 days 
after C. Diff diagnosis. 
Yes, survival analysis was 
performed instead of 
logistic regression 
analysis, to avoid survival 
bias associated with high 
mortality rates in the ICU. 
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Table 3 Case Control Validity 
Case-Control Dial Aseeri Jayatilaka 
Were cases and controls 
similar with respect to the 
indication or circumstances 
that would lead to 
exposure? 
Yes,  control subjects 
were selected from a list 
obtained from the 
hospital pharmacy of 
patients who had been 
prescribed any 
antibiotics while in 
hospital during the 
study period-other risk 
factors were controlled 
for. 
Yes, case and controls 
were matched on a 1:1 
ratio based on the 
following factors, a)date 
of hospital admission, b) 
antibiotic use, c) gender 
d) age group e) patient 
location at time of 
admission f) room time 
at admission  **with 
specific antibiotics 
broken down to number, 
type and duration. 
Yes, they are all 
hospital inpatients. 
Although this, some 
were accepted that 
were already on PPI's. 
This would bias the 
data. 
Were the circumstances and 
methods for determining 
exposure similar for case 
and controls? 
No, cases were defined 
as all consecutive ward 
patients with C. diff. 
Controls were selected 
from a list obtained 
from the hospital 
pharmacy, but the 
methods for 
determining exposure 
were the same. 
Yes, cases and controls 
were both identified by 
the inclusion and 
exclusion criteria. The 
only difference in the 
two groups was diarrhea, 
and/or a positive C. Diff 
toxin for the cases. 
Yes, for each of the 
cases two controls 
were found and 
admitted during the 
same time period, and 
age and sex were 
matched to the C. Diff 
positive case 
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